LGALS3 and non-Hodgkin lymphoma: Taken together with the in vitro observations, the general suppression of tumor growth in the absence of galectin-3 in vivo suggests (1) that host galectin-3-mediated antilymphoma activity is required to sustain net tumor growth and/or (2) that additional function(s) of galectin-3 drive key pro-oncogenic mechanisms in NHL.